150 related articles for article (PubMed ID: 24807015)
1. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Yang X; Yang K; Kuang K
Curr Oncol Rep; 2014 Jun; 16(6):390. PubMed ID: 24807015
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib in non small cell lung cancer.
Costanzo R; Piccirillo MC; Sandomenico C; Carillio G; Montanino A; Daniele G; Giordano P; Bryce J; De Feo G; Di Maio M; Rocco G; Normanno N; Perrone F; Morabito A
J Biomed Biotechnol; 2011; 2011():815269. PubMed ID: 21660144
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials.
Lai X; Zeng J; Xiao Z; Xiao J
Medicine (Baltimore); 2024 Jun; 103(23):e38277. PubMed ID: 38847673
[TBL] [Abstract][Full Text] [Related]
4. Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.
Vale CL; Burdett S; Fisher DJ; Navani N; Parmar MK; Copas AJ; Tierney JF
Clin Lung Cancer; 2015 May; 16(3):173-182.e4. PubMed ID: 25547901
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.
Goss G; Ferry D; Wierzbicki R; Laurie SA; Thompson J; Biesma B; Hirsch FR; Varella-Garcia M; Duffield E; Ataman OU; Zarenda M; Armour AA
J Clin Oncol; 2009 May; 27(13):2253-60. PubMed ID: 19289623
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
Zhang W; Wei Y; Yu D; Xu J; Peng J
BMC Cancer; 2018 Aug; 18(1):780. PubMed ID: 30068310
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials.
Mangla B; Mittal P; Kumar P; Aggarwal G
Med Oncol; 2024 Jun; 41(7):173. PubMed ID: 38864966
[TBL] [Abstract][Full Text] [Related]
8. Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report.
Bian S; Tang X; Ye S; Lei W
Respir Med Case Rep; 2020; 31():101228. PubMed ID: 32995264
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.
Asami K; Atagi S
World J Clin Oncol; 2014 Oct; 5(4):646-59. PubMed ID: 25302168
[TBL] [Abstract][Full Text] [Related]
10. Afatinib for the treatment of metastatic non-small cell lung cancer.
Joshi M; Rizvi SM; Belani CP
Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
[TBL] [Abstract][Full Text] [Related]
11. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Haspinger ER; Agustoni F; Torri V; Gelsomino F; Platania M; Zilembo N; Gallucci R; Garassino MC; Cinquini M
Crit Rev Oncol Hematol; 2015 May; 94(2):213-27. PubMed ID: 25523487
[TBL] [Abstract][Full Text] [Related]
12. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Burotto M; Ali SA; O'Sullivan Coyne G
Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the treatment of non-small cell and small cell lung cancer.
Stinchcombe TE
F1000Prime Rep; 2014; 6():117. PubMed ID: 25580271
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
15. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review.
Ellis PM; Coakley N; Feld R; Kuruvilla S; Ung YC
Curr Oncol; 2015 Jun; 22(3):e183-215. PubMed ID: 26089730
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
17. Novel agents in development for advanced non-small cell lung cancer.
Stinchcombe TE
Ther Adv Med Oncol; 2014 Sep; 6(5):240-53. PubMed ID: 25342991
[TBL] [Abstract][Full Text] [Related]
18. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
20. Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials.
Melosky B
Front Oncol; 2014; 4():244. PubMed ID: 25309870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
